XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and contingencies - Neurocrine Collaboration Agreement - (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2019
USD ($)
shares
Mar. 31, 2019
USD ($)
item
$ / shares
shares
Jun. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Allocation of Transaction Price              
Revenue recognized           $ 1,214  
Deferred revenue     $ 10,881 $ 12,096   10,881  
Related party collaboration receivable     151 732   151  
Neurocrine Collaboration Agreement | FA Program              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Percentage of profit or loss under co-co option   40.00%          
Neurocrine Collaboration Agreement | Neurocrine              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Number of collaboration programs | item   4          
Number of discovery programs | item   2          
Programs added later | item   2          
Discovery programs under development | item   2          
Number of targets | item   8          
Upfront payment $ 115,000 $ 115,000          
Purchase of common stock, shares | shares 4,179,728 4,179,728          
Purchase of common stock $ 5,000 $ 50,000          
Price per share | $ / shares   $ 11.9625          
Aggregate maximum milestone payments to be received from collaborative partner   $ 170,000          
Estimated cost reimbursement 431,100     $ 80,000   79,700  
Termination period   10 years          
Period of advance notice for termination prior to first commercial sale   180 days          
Period of advance notice for termination after first commercial sale   1 year          
Discount related to equity investment 27,600            
Equity investment 50,000            
Allocation of Transaction Price              
Allocation of variable consideration     79,668     79,668  
Allocation of fixed consideration 92,400   92,382     92,382  
Revenue recognized     700   $ 1,400 1,400 $ 7,900
Cumulative catch up of revenue recognized           900  
Costs to obtain collaboration agreement     800     800  
Consideration received $ 5,000            
Neurocrine Collaboration Agreement | Neurocrine | Maximum              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Percentage of reduction in royalty payments   50.00%          
Neurocrine Collaboration Agreement | Neurocrine | VY-AADC              
Allocation of Transaction Price              
Allocation of variable consideration     53,863     53,863  
Allocation of fixed consideration     49,045     49,045  
Neurocrine Collaboration Agreement | Neurocrine | FA Program              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Percentage of profit or loss under co-co option   60.00%          
Allocation of Transaction Price              
Allocation of variable consideration     17,088     17,088  
Allocation of fixed consideration     20,647     20,647  
Neurocrine Collaboration Agreement | Neurocrine | Discovery and FA Programs              
Allocation of Transaction Price              
Allocation of fixed consideration     42,200     42,200  
Neurocrine Collaboration Agreement | Neurocrine | Discovery program 1              
Allocation of Transaction Price              
Allocation of variable consideration     5,355     5,355  
Allocation of fixed consideration     14,443     14,443  
Neurocrine Collaboration Agreement | Neurocrine | Discovery program 2              
Allocation of Transaction Price              
Allocation of variable consideration     3,362     3,362  
Allocation of fixed consideration     $ 8,247     $ 8,247  
Neurocrine Collaboration Agreement | Neurocrine | Development and regulatory milestones | FA Program              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Aggregate maximum milestone payments to be received from collaborative partner   $ 195,000          
Neurocrine Collaboration Agreement | Neurocrine | Development and regulatory milestones | Discovery program 1              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Aggregate maximum milestone payments to be received from collaborative partner   130,000          
Neurocrine Collaboration Agreement | Neurocrine | Commercial Milestone              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Per Milestone, maximum milestone payments to be received from collaborative partner   275,000          
Aggregate maximum milestone payments to be received from collaborative partner   $ 1,100,000